Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus

References

Page 1

	Year	Citations
Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study Leif Sparre Hermann, Bengt Scherstén, Per-Olof Bitzén, Diabetes Care	1994	347
Symptomatic Hypoglycemia in NIDDM Patients Treated With Oral Hypoglycemic Agents Adrian Jennings, R Malcolm Wilson, John D. Ward Diabetes Care	1989	194
Sulphonylureas and hypoglycaemia R E Ferner, H. A. W. Neil BMJ PhysiologyHematologyHypoxia (Medicine)PathologyClinical Chemistry	1988	134
Antihyperglycaemic Efficacy, Response Prediction and Dose—Response Relations of Treatment with Metformin and Sulphonylurea, Alone and in Primary Combination L. S. Hermann, Bengt Scherstén, Arne Melander Diabetic Medicine	1994	87
Metabolic and Hemodynamic Effects of Metformin and Glibenclamide in Normotensive NIDDM Patients Juliana C.N. Chan, Brian Tomlinson, Julia Critchley, Diabetes Care	1993	81
The Effect of Glibenclamide and Metformin on Serum Lipoproteins in Type 2 Diabetes S. G. H. Rains, Gregory Wilson, W. Richmond, Diabetic Medicine ObesityMetabolic SyndromeDiabetes ManagementBody CompositionCardiovascular Disease	1988	75
Glibenclamide, but Not Acarbose, Increases Leptin Concentrations Parallel to Changes in Insulin in Subjects With NIDDM Steven M. Haffner, M Hanefeld, Sabine Fischer, Diabetes Care ObesityMetabolic SyndromeLeptin ConcentrationLeptin ConcentrationsDiabetes Management	1997	40
Plasma Levels of Glibenclamide in Diabetic Patients during its Routine Clinical Administration Determined by a Specific Radioimmunoassay Ayako Matsuda, T. Kuzuya, Yasuo Sugita, Hormone and Metabolic Research Metabolic SyndromeDiabetes ManagementPlasma LevelsMedicineDiabetes	1983	30
Comparison of Pharmacokinetics and Pharmacodynamics of Short- and Long-Term Glyburide Therapy in NIDDM Linda A. Jaber, Edward J. Antal, Richard L. Slaughter, Diabetes Care	1994	29
Blood Glucose Variations and Clinical Experience with Glibenclamide in Diabetes Mellitus D. J. O’Sullivan, W. F. Cashman BMJ Metabolic SyndromeDiabetes ManagementBlood Glucose VariationsToxic EffectsDiabetes	1970	21

Page 1